The Motley Fool

Why Eclipx, REA Group, Regis Resources, & Starpharma shares zoomed higher today

The S&P/ASX 200 index has followed the lead of U.S. markets and started the week on a disappointing note. In afternoon trade the benchmark index is down 0.9% to 6,341.2 points.

Four shares that have defied the market and zoomed higher today are listed below. Here’s why these shares have started the week strongly:

The Eclipx Group Ltd (ASX: ECX) share price has surged a further 24% higher to $1.39. The fleet management company’s shares have been on fire since the release of its half year results and update on its simplification plan late last week. One broker that liked what it saw was Credit Suisse. This morning it upgraded Eclipx’s shares to an outperform rating and lifted its price target from 88 cents to $1.40.

The REA Group Limited (ASX: REA) share price has climbed 2% to $90.65 after CoreLogic released its latest house price data. Although house prices in Melbourne and Sydney continued to slide in May, it was the smallest monthly decline in 12 months. Investors may believe that this is a sign that house prices are close to bottoming in these key markets. This could lead to a rebound in listings for REA Group in the near term.

The Regis Resources Limited (ASX: RRL) share price has zoomed 7% higher to $4.77 after the gold price surged higher on Friday. Pleasingly for the gold miners, the precious metal has continued its charge during Asian trade and is up a further 0.5% to US$1,317.30. Concerns over a global trade war and a recession in the United States have supported the gold price. As has speculation that the U.S. Federal Reserve could soon cut rates.

The Starpharma Holdings Limited (ASX: SPL) share price has pushed 3.5% higher to $1.35 after announcing a new agreement with UK-based pharmaceutical giant AstraZeneca. According to the release, the two parties have signed a Development and Option Agreement which will see Starpharma progress the development of a dendrimer enhanced product (DEP) version of an undisclosed AstraZeneca major marketed oncology medicine.

Missed these gains? Then you won't want to miss out on this hot small cap stock.

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more


James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended REA Group Limited and Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.